Diagnósticos da América Past Earnings Performance
Past criteria checks 0/6
Diagnósticos da América's earnings have been declining at an average annual rate of -69.9%, while the Healthcare industry saw earnings growing at 12.2% annually. Revenues have been growing at an average rate of 28.3% per year.
Key information
-69.9%
Earnings growth rate
-66.0%
EPS growth rate
| Healthcare Industry Growth | 11.6% |
| Revenue growth rate | 28.3% |
| Return on equity | -15.4% |
| Net Margin | -8.0% |
| Next Earnings Update | 15 May 2024 |
Recent past performance updates
Recent updates
Risks To Shareholder Returns Are Elevated At These Prices For Diagnósticos da América S.A. (BVMF:DASA3)
Mar 21
Diagnósticos da América (BVMF:DASA3) May Have Issues Allocating Its Capital
Feb 04Is Diagnósticos da América (BVMF:DASA3) A Risky Investment?
Jan 08Insufficient Growth At Diagnósticos da América S.A. (BVMF:DASA3) Hampers Share Price
Dec 18Diagnósticos da América (BVMF:DASA3) Is Reinvesting At Lower Rates Of Return
Sep 20Is Diagnósticos da América (BVMF:DASA3) Using Too Much Debt?
Aug 25Diagnósticos da América S.A. (BVMF:DASA3) Looks Inexpensive But Perhaps Not Attractive Enough
Jun 27Diagnósticos da América (BVMF:DASA3) May Have Issues Allocating Its Capital
Apr 17Diagnósticos da América (BVMF:DASA3) Seems To Be Using A Lot Of Debt
Mar 13Returns On Capital At Diagnósticos da América (BVMF:DASA3) Paint A Concerning Picture
Dec 14Does Diagnósticos da América (BVMF:DASA3) Have A Healthy Balance Sheet?
Nov 09Diagnósticos da América (BVMF:DASA3) May Have Issues Allocating Its Capital
Aug 19Here's Why Diagnósticos da América (BVMF:DASA3) Has A Meaningful Debt Burden
Jul 15Diagnósticos da América (BVMF:DASA3) May Have Issues Allocating Its Capital
May 06Results: Diagnósticos da América S.A. Delivered A Surprise Loss And Now Analysts Have New Forecasts
Apr 01These 4 Measures Indicate That Diagnósticos da América (BVMF:DASA3) Is Using Debt Reasonably Well
Mar 02Diagnósticos da América (BVMF:DASA3) Could Be Struggling To Allocate Capital
Jan 25Diagnósticos da América (BVMF:DASA3) Might Be Having Difficulty Using Its Capital Effectively
Oct 10Is Diagnósticos da América (BVMF:DASA3) A Risky Investment?
Sep 13There Are Reasons To Feel Uneasy About Diagnósticos da América's (BVMF:DASA3) Returns On Capital
Jun 27Diagnósticos da América (BVMF:DASA3) Has A Somewhat Strained Balance Sheet
May 31We're Watching These Trends At Diagnósticos da América (BVMF:DASA3)
Feb 25Shareholders of Diagnósticos da América (BVMF:DASA3) Must Be Delighted With Their 634% Total Return
Jan 03
These 4 Measures Indicate That Diagnósticos da América (BVMF:DASA3) Is Using Debt Extensively
Dec 07Revenue & Expenses BreakdownBeta
How Diagnósticos da América makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 14,252 | -1,138 | 2,975 | 0 |
| 30 Sep 23 | 14,213 | -843 | 3,044 | 0 |
| 30 Jun 23 | 13,869 | -752 | 3,018 | 0 |
| 31 Mar 23 | 13,527 | -590 | 2,874 | 0 |
| 31 Dec 22 | 13,129 | -387 | 2,864 | 0 |
| 30 Sep 22 | 12,523 | -340 | 2,930 | 0 |
| 30 Jun 22 | 11,862 | -177 | 2,814 | 0 |
| 31 Mar 22 | 11,178 | -177 | 3,136 | 0 |
| 31 Dec 21 | 10,419 | -227 | 3,066 | 0 |
| 30 Sep 21 | 9,973 | -36 | 3,105 | 0 |
| 30 Jun 21 | 9,280 | -60 | 2,736 | 0 |
| 31 Mar 21 | 7,959 | -85 | 1,997 | 0 |
| 31 Dec 20 | 7,039 | -151 | 1,635 | 0 |
| 30 Sep 20 | 5,887 | -191 | 1,269 | 0 |
| 30 Jun 20 | 4,986 | -198 | 1,271 | 0 |
| 31 Mar 20 | 4,795 | -19 | 1,249 | 0 |
| 31 Dec 19 | 4,365 | 125 | 1,148 | 0 |
| 30 Sep 19 | 4,238 | 127 | 1,129 | 0 |
| 30 Jun 19 | 4,096 | 158 | 1,097 | 0 |
| 31 Mar 19 | 3,992 | 168 | 1,070 | 0 |
| 31 Dec 18 | 3,933 | 184 | 1,046 | 0 |
| 30 Sep 18 | 3,886 | 210 | 899 | 0 |
| 30 Jun 18 | 3,733 | 175 | 875 | 0 |
| 31 Mar 18 | 3,545 | 136 | 841 | 0 |
| 31 Dec 17 | 3,399 | 131 | 823 | 0 |
| 30 Sep 17 | 3,259 | 129 | 791 | 0 |
| 30 Jun 17 | 3,178 | 152 | 715 | 0 |
| 31 Mar 17 | 3,138 | 169 | 665 | 0 |
| 31 Dec 16 | 3,041 | 95 | 652 | 0 |
| 30 Sep 16 | 2,965 | 90 | 596 | 0 |
| 30 Jun 16 | 2,899 | 39 | 592 | 0 |
| 31 Mar 16 | 2,864 | 29 | 606 | 0 |
| 31 Dec 15 | 2,794 | 24 | 605 | 0 |
| 30 Sep 15 | 2,731 | 4 | 604 | 0 |
| 30 Jun 15 | 2,731 | 38 | 610 | 0 |
| 31 Mar 15 | 2,691 | 58 | 588 | 0 |
| 31 Dec 14 | 2,698 | 88 | 576 | 0 |
| 30 Sep 14 | 2,666 | 135 | 604 | 0 |
| 30 Jun 14 | 2,584 | 127 | 564 | 0 |
| 31 Mar 14 | 2,528 | 130 | 532 | 0 |
| 31 Dec 13 | 2,448 | 125 | 490 | 0 |
| 30 Sep 13 | 2,406 | 93 | 432 | 0 |
| 30 Jun 13 | 2,349 | 84 | 420 | 0 |
Quality Earnings: DASA3 is currently unprofitable.
Growing Profit Margin: DASA3 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DASA3 is unprofitable, and losses have increased over the past 5 years at a rate of 69.9% per year.
Accelerating Growth: Unable to compare DASA3's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DASA3 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (38.6%).
Return on Equity
High ROE: DASA3 has a negative Return on Equity (-15.4%), as it is currently unprofitable.